Target Name: CD69
NCBI ID: G969
Other Name(s): Leukocyte surface antigen Leu-23 | early T-cell activation antigen p60 | early lymphocyte activation antigen | Early T-cell activation antigen p60 | CD69_HUMAN | Activation inducer molecule | AIM | CD69 antigen (p60, early T-cell activation antigen) | CD69 molecule | Early activation antigen CD69 | EA1 | C-type lectin domain family 2, member C | C-type lectin domain family 2 member C | BL-AC/P26 | GP32/28 | MLR-3 | Leu-23 | leukocyte surface antigen Leu-23 | activation inducer molecule (AIM/CD69) | CLEC2C

CD69: A Potential Drug Target and Biomarker for Leukocyte Surface Antigen Leu-23

Leukocyte surface antigen Leu-23 (CD69) is a protein that is expressed in various types of white blood cells, including leukocytes, erythrocytes, and epithelial cells. CD69 is a member of the integrin alpha-6 (Integrin alpha-6, CD69) family and is involved in cell adhesion, migration, and invasion. It is also a key receptor for various cytokines and chemokines, which play a crucial role in the regulation of immune and inflammatory responses.

CD69 has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In this article, we will explore the biology and potential therapeutic applications of CD69 in more detail.

CD69 Expression and Functions

CD69 is a transmembrane protein that is expressed in various types of white blood cells, including leukocytes, erythrocytes, and epithelial cells. It is highly expressed in human leukocytes, including neutrophils, and is also found in various types of cancer cells. CD69 is involved in several cellular processes, including:

1. Cell Adhesion and Migration: CD69 is a key receptor for various cytokines and chemokines, which play a crucial role in the regulation of cell adhesion, migration, and invasion. It is involved in the formation of tight junctions between epithelial cells, which are responsible for barrier function.
2. Inositol Trisphosphate (IP3) Signaling: CD69 is involved in the regulation of IP3 signaling, which is a signaling pathway that is involved in a variety of cellular processes, including intracellular signaling, cell signaling, and neurotransmission.
3. Leukocyte Activation and Inflammation: CD69 is involved in the regulation of leukocyte activation and inflammation. It is involved in the signaling pathway between T cells and dendritic cells, which are critical for the regulation of immune responses.

Potential Therapeutic Applications

CD69 has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Here are some of the potential therapeutic applications of CD69:

1. Cancer: CD69 has been shown to be involved in the regulation of cancer cell growth, survival, and angiogenesis. It is a good candidate for targeting cancer cells that are characterized by the loss of CD69.
2. Autoimmune Disorders: CD69 is involved in the regulation of immune responses, including the regulation of T cell activation and regulation of inflammation. It is a potential target for the treatment of autoimmune disorders.
3. Neurodegenerative Diseases: CD69 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It is a potential target for the development of neurodegenerative disease therapies.

Conclusion

CD69 is a protein that is involved in several cellular processes that are critical for the regulation of white blood cells. It has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Further research is needed to fully understand the biology of CD69 and its potential therapeutic applications.

Protein Name: CD69 Molecule

Functions: Involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets

More Common Targets

CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P